Production of no-carrier-added
Lu for radioimmunotherapy
放射免疫療法のための無担体
Luの製造法の開発
渡辺 智; 橋本 和幸; 渡邉 茂樹; 飯田 靖彦*; 花岡 宏史*; 遠藤 啓吾*; 石岡 典子
Watanabe, Satoshi; Hashimoto, Kazuyuki; Watanabe, Shigeki; Iida, Yasuhiko*; Hanaoka, Hirofumi*; Endo, Keigo*; Ishioka, Noriko
Lutetium-177 is considered to have potential for application in radioimmunotherapy, because it emits
-particles (E
=498 keV) suitable to penetrate small tumors and its physical half-life of 6.734 days is long enough for
Lu-labeled antibodies to accumulate to tumor sites. In addition, real time imaging of biodistribution can be done by using the
Lu, because the energy of
-rays (113 keV and 208 keV) emitted from
Lu is particularly suitable for imaging by single photon emission computed tomography. We can produce
Lu by the
Lu (n,
)
Lu process and the
Yb(n,
)
Yb (T
=1.911 h)
Lu process. In the field of radioimmunotherapy using labeled monoclonal antibodies, to enhance the effect of therapy, no-carrier-added (nca)
Lu produced in the
Yb(n,
)
Yb (T
=1.911 h) 
Lu process with high specific radioactivity are required. Therefore, in the present paper, production of highly-purified nca
Lu from macroscopic amounts of the ytterbium target is developed.